540 Baseline mTOR transcriptional signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors

• Arun Rajan,
• Jeffrey Schlom,
• Chen Zhao,
• James Gulley,
• Renee Donahue,
• Andrew Mammen,
• Jinguo Chen,
• Matthew Mule,
• Andrew Martins,
• Iago Pinal Fernandez,
• John Tsang

Affiliations

Arun Rajan

2 Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

Jeffrey Schlom

Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA

Chen Zhao

State Key Laboratory of Genetic Engineering, School of Life Sciences and Obstetrics & Gynecology Hospital of Fudan University, Shanghai, China

James Gulley

NIH, Bethesda, MD, USA

Renee Donahue

NIH, Bethesda, MD, USA

Andrew Mammen

Aff3 0000 0001 2237 2479grid.420086.8Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health Bethesda MD USA

Jinguo Chen

Aff1 grid.94365.3d0000000122975165Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center, Trans-NIH Center for Human Immunology (CHI)National Institutes of Health Bethesda MD USA

Matthew Mule

3NIAID, North Bethesda, USA

Andrew Martins

3NIAID, North Bethesda, USA

Iago Pinal Fernandez

4NIAMS, North Bethesda, USA

John Tsang

3NIAID, North Bethesda, USA